Alliance Global Partners Upgrades Aptose Biosciences (TSE:APS) to “Strong-Buy”

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) was upgraded by Alliance Global Partners to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Aptose Biosciences Trading Down 7.2 %

APS stock opened at C$4.36 on Thursday. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The firm has a market cap of C$187.73 million, a P/E ratio of -0.87 and a beta of 1.36. Aptose Biosciences has a 1-year low of C$0.16 and a 1-year high of C$5.29. The business’s 50 day moving average is C$8.67 and its 200-day moving average is C$12.27.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.